A Study of SGN-STNV in Advanced Solid Tumors
Public ClinicalTrials.gov record NCT04665921. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Study of SGN-STNV in Advanced Solid Tumors
Study identification
- NCT ID
- NCT04665921
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Seagen Inc.
- Industry
- Enrollment
- 111 participants
Conditions and interventions
Conditions
- Appendiceal Adenocarcinoma
- Carcinoma, Non-Small Cell Lung
- Colorectal Neoplasms
- Endometrial Neoplasms
- Esophageal Neoplasms
- Exocrine Pancreatic Adenocarcinoma
- Gastroesophageal Junction Carcinoma
- HER2 Negative Breast Neoplasms
- Ovarian Neoplasms
- Pseudomyxoma Peritonei
- Stomach Neoplasms
- Uterine Cervical Neoplasms
Interventions
- SGN-STNV Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 17, 2021
- Primary completion
- Feb 29, 2024
- Completion
- Feb 29, 2024
- Last update posted
- Feb 6, 2025
2021 – 2024
United States locations
- U.S. sites
- 12
- U.S. states
- 9
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| The Angeles Clinic and Research Institute | Los Angeles | California | 90025 | — |
| University of California, San Francisco | HDFCCC - Hematopoietic Malignancies | San Francisco | California | 94158 | — |
| Shands Cancer Center / University of Florida | Gainesville | Florida | 32610 | — |
| University of Miami | Miami | Florida | 33136 | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| South Texas Accelerated Research Therapeutics Midwest | Grand Rapids | Michigan | 49546 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| University Hospitals Cleveland Medical Center | Cleveland | Ohio | 44106 | — |
| Oregon Health and Science University | Portland | Oregon | 97239-3098 | — |
| Magee Womens Hospital of UPMC | Pittsburgh | Pennsylvania | 15213 | — |
| South Texas Accelerated Research Therapeutics | San Antonio | Texas | 78229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04665921, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 6, 2025 · Synced May 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04665921 live on ClinicalTrials.gov.